New CAR-T therapy targets tough lung cancer in early trial
NCT ID NCT07246304
First seen Jan 03, 2026 · Last updated May 19, 2026 · Updated 18 times
Summary
This early-phase study tests a new treatment called TC-D101 for people with a specific type of advanced small cell lung cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) to target a protein called DLL3 on cancer cells. The main goals are to check safety and find the best dose, while also seeing if it helps shrink tumors. About 24 adults aged 18-75 who meet eligibility criteria will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Jinling Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.